Tom McLain has over 20 years of experience and a proven track record evolving diagnostics and biopharmaceutical companies from early-stage ventures to successful commercial organizations. Most recently as Chief Executive Officer (CEO) of Vermillion, a medical diagnostics company focused on women’s health, Mr. McLain led a strategic transformation that resulted in a fivefold increase in the company’s market capitalization. Prior to joining Vermillion, Mr. McLain was the CEO of Claro Scientific, a diagnostics start-up with a novel optics-based platform technology. He also previously served as chairman, CEO and president of Nabi Biopharmaceuticals where he led the evolution of a plasma supply-based business into a fully integrated biopharmaceutical company. Over his career, Mr. McLain has raised over $1 billion in new capital and structured numerous successful commercial alliances, joint ventures and research collaborations. Mr. McLain also served as a director, chairman of the health, safety, environment and security committee and member of the audit and finance committees at Eastman Chemical Company and as chairman of the board of Nabi Biopharmaceuticals. He has been active in the life sciences industry, serving as Chairman of the Board of BioFlorida for seven years and as a board member of the Biotechnology Industry Organization and the Southeastern Medical Device Association. Mr. McLain earned his BA at the College of the Holy Cross, and his MBA from the University of Rochester.